This content is machine translated Newly diagnosed multiple myeloma Does a proteasome inhibitor offer new therapeutic options? One study discussed at the ASH meeting involved a regimen consisting of oral MLN9708 administered twice weekly plus lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma. It concludes…
